The selection of the right antibiotic and right dose necessitates clinicians understand the contribution of pharmacokinetic variability stemming from age-related physiologic maturation and the pharmacodynamics to optimize drug exposure for clinical response. The complexity of selecting the right dose arises from the multiplicity of pediatric age groups, from premature neonates to adolescents. Body size and age (which relate to organ function) must be incorporated to optimize antibiotic dosing in this vulnerable population. In the effort to optimize and individualize drug dosing regimens, clinical pharmacometrics that incorporate population-based pharmacokinetic modeling, Bayesian estimation, and Monte Carlo simulations are utilized as a quantitative approach to understanding and predicting the pharmacology and clinical and microbiologic efficacy of antibiotics. In addition, opportunistic study designs and alternative blood sampling strategies can serve as practical approaches to ensure successful conduct of pediatric studies. This review article examines relevant literature on optimization of antibiotic pharmacotherapy in pediatric populations published within the last decade. Specific pediatric antibiotic data, including beta-lactam antibiotics, aminoglycosides, and vancomycin, are critically evaluated.
Effective pharmacotherapy in pediatric patients with infection requires the integration of pertinent data on the antibiotic, bacterial pathogen, and patient. In addition to appropriate antibiotic selection based on the susceptibility of the pathogen and the site of infection, optimizing antibiotic therapy to achieve the desired outcome in pediatric patients necessitates the understanding of growth and development related to age for both physiologic and immunologic processes that govern drug absorption, distribution, metabolism, and elimination, as well as maturation of granulocyte, lymphocyte, and humoral immune function. Physiologic development may alter the pharmacokinetics (PK) and impact the pharmacodynamics (PD) of drugs. In selecting the right antibiotic and dose, clinicians must understand the contribution of PK variability stemming from age-related physiologic maturation and the PD to optimize antibiotic exposure for clinical response. 1 While the immature nature of the immune system in neonates and infants may potentially affect the PD of antibiotics, this article focuses on the effect of PKPD alterations stemming from physiologic changes that occur with age on antibiotic therapy. A PubMed search for publications up to November 2017was conducted using key terms relevant to pediatric PKPD and specific antibiotics reviewed in this article. Key articles, independent of year of publication, were selected to highlight important attributes of pediatric pharmacology. Recent articles with new information related to pediatric pharmacology and specific antibiotics, particularly focusing on literature within the past decade, were critically reviewed and are presented in this review.
Pharmacokinetics: Alterations Stemming From Growth and Development
The two key factors stemming from physiologic maturation that contribute to PK alterations in pediatric patients are body size and organ function (which is defined by age). The complexity of PK variability arises S109 from the multiple pediatric age groups, from premature neonates to adolescents. "Pediatric patients" denotes all pediatric age groups from birth to 18 years, including premature neonate (born before 37 weeks' gestation), neonates (within first month of life), infants (1 to 12 months), children (1 to 12 years), and adolescents (13 to 18 years). The neonatal and infant periods comprise the most dramatic maturational developments that affect a drug's PK. While age-related physiologic maturation continues into childhood, the most prominent differences, compared with adults, are evident in neonates and infants. Table 1 describes the maturational processes that affect a drug's absorption, distribution, metabolism, and renal elimination in pediatric patients compared with adults. The age group in which the maturational process reaches adult values are also provided.
Body Size
Drug dosing in pediatric patients should be scaled to body size, expressed as milligram per kilogram. Total body weight is a common and appropriate measure to use for drug dosing in normal-sized children. However, pediatric drug doses cannot be normalized directly from an adult dose using total body weight (ie, adult dose in milligram per kilogram) when pediatric dosing data are unavailable. This is because drug elimination, particularly via the renal route, is nonlinear to weight. 2 Two contrasting consequences arise from this nonlinear relationship: the underestimation of drug clearance (CL) in children and its overestimation in adults. 2 While total body weight is an inadequate body size descriptor to apply in pediatric drug dosing that is derived from adult data, a child's body size can be referenced to a 70-kg adult using allometric scalinga coefficient of 1 for volume distribution (Vd; weight 1 ) and 0.75 for CL (weight 0.75 ). 3 This allometric approach to the prediction of drug CL has been applied in children older than 5 years, including children with cystic fibrosis (CF) and, possibly, obesity (albeit other factors play a role in children who are obese). [4] [5] [6] The exponent of 0.75 has been used to allometrically scale weight to describe the maturation of glomerular filtration rate (GFR) in pediatric patients, including neonates. 7 The 0.75 allometric scaling was superior to body surface area (which uses an exponent of 0.67) in measuring GFR, liver and kidney volumes, and cardiac output. 2 However, for neonates and infants, this exponent may not be applicable for predicting the CL of some drugs, especially those that have elimination outside of glomerular filtration. 8 Ideally, to optimize age-specific dosing across the pediatric age spectrum, the exact value used for allometric scaling should be derived for each individual drug through PK studies. Age Similar to weight, age is another significant factor to integrate when optimizing drug dosing in neonates, infants, and young children because it correlates well with organ function responsible for the maturation of CL, both renal and hepatic. In the healthy pediatric population, age defines organ function. The presence of diseases, such as CF, may alter organ function. Relative to body mass, the size and weight of organs, specifically the kidneys and liver, which are responsible for drug CL, are several-fold greater in younger children compared with adults. Clearance accounts for both metabolism and elimination of a drug from the body and largely determines the maintenance dose. Renal elimination, including reduced GFR, tubular secretion, and reabsorption, is immature in neonates and infants. Because of this, the CL of antibiotics that undergo elimination primarily via GFR (including certain beta-lactams, aminoglycosides, and vancomycin) are decreased in neonates and infants relative to older pediatric age groups. This may lead to increased drug exposure in neonates and infants and potentially increases the risk for toxicity, particularly nephrotoxicity for aminoglycosides, if the dosing is not adjusted.
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Within the first 2 weeks of life, a rapid surge in renal function is observed that is due to an increase in renal blood flow. 10, 11 This marks the most prominent change within the first year of life and occurs nonlinearly with age during this interval. The nonlinear relationship between age and renal function follows an evident plateau of drug dosing, expressed as milligram per kilogram. Consequently, increasing drug dosage is necessary up to a certain age, when dosage then decreases to that appropriate for adults.
An in-depth discussion of age (usually referred as postnatal age or chronologic age) is crucial with respect to neonates because nephrogenesis, which is responsible for the increase in the GFR in utero, requires completion of 36 weeks' gestation. 10, 11 By definition, gestational (or menstrual) age is the time between the first day of the last normal menstrual period and birth; postnatal age accounts for the duration of life after birth; and postmenstrual age incorporates both gestational and postnatal age. For premature neonates born before 36 weeks' gestation, a drug's PK may depend on more than postnatal (or chronologic) age because nephrogenesis has not occurred. The use of postnatal age compared with postmenstrual age as an indicator for the maturation of drug elimination may, therefore, be suboptimal for premature neonates. 3 In fact, postmenstrual age was more useful than postnatal age in describing GFR in premature and fullterm neonates. 7 In a large pediatric study of pooled data from 923 participants ranging from 22 weeks' postmenstrual age to 31 years, allometric scaling was applied to predict and compare GFR between pediatric participants and adults. Interestingly, half of the adult GFR (ie, approximately 60 mL/min per 70 kg) was reached at 48 weeks of postmenstrual age and 90% of the adult GFR, at 1 year of age. 7 Age becomes less influential in late childhood and adolescence.
Maturation of hepatic pathways that affect drugs undergoing metabolic transformation or elimination occurs at diverse rates at different ages, ranging from the first months to years of life. The body's primary organ for drug metabolism, the liver, produces microsomal cytochrome P450 enzymes at birth. The activity of most of these enzymes is reduced during infancy, with maturation occurring from infancy into late childhood, depending on the specific enzyme (Table 1) . 2 Consequently, the metabolic CL, particularly the glucuronidation reaction, is lower in neonates and infants than in adults. Two exceptions to the underdeveloped liver function in neonates and infants are methyltransferase and sulfotransferase, respectively, for which enhanced activity is observed.
The different rates of hepatic maturation, along with the complexity of the hepatic CL of drugs that may use different mechanisms at varying degrees, precludes accurate prediction of drug dosages. Enzymatic maturation has been described using the sigmoidal Hill equation and coefficients that incorporate postmenstrual age and the maturation half-time (TM 50 ). 2 In neonates and infants, calculations based on postmenstrual age are more accurate than calculations based on other types of age because it accounts for maturation that occurs during gestation.
In addition to renal and hepatic functions that contribute to a drug's metabolism and elimination (ie, CL) and therefore dosing, age also influences drug distribution through body water or fat composition and plasma protein binding. Body composition and protein binding change with age. Drug distribution, which is represented by Vd, equates to the total amount of drug distributed within the blood and tissues. Drugs that remain in the circulation and distribute mainly in the extracellular fluid compartment (eg, hydrophilic drugs, including aminoglycosides and linezolid) usually possess a relatively low Vd. In contrast, drugs that distribute intracellularly or well in tissues generally have a relatively high Vd. Because physiologic maturation that occurs with age alters body composition and plasma protein binding, the Vd of drugs in pediatric patients changes accordingly (Table 1) . For example, the augmented total body and extracellular water content evident in neonates and young infants translates to enhanced Vd of aminoglycosides and linezolid and, consequently, the need for increased loading doses (milligram per kilogram) to achieve adequate drug exposure (ie, usually by peak concentration). 9, 12 The reverse is observed for highly lipophilic drugs such as clindamycin. 13 Another important factor that affects drug distribution is plasma protein binding. The decrease in both the concentration and affinity of plasma binding proteins such as albumin and alpha-1-acid glycoprotein in neonates, infants, and young children alters the distribution of drugs, resulting in an increase in the unbound moiety (which is the free, pharmacologically active drug) ( Table 1) . For example, vancomycin demonstrates partial binding to albumin, with a reported range of 30% to 60% in adults. Compared with adults, the decrease in albumin binding evident in pediatric patients results in a significant increase in the unbound vancomycin fraction, to approximately 80%. 14 In addition, a recent study showed that the Vd of clindamycin in children who are non-obese and children who are obese was proportional to concentrations of alpha-1-acid glycoprotein and albumin because it binds highly to both proteins. 15 Plasma membrane transporters mediate the absorption, distribution, and excretion of drugs. The activities of these transporters are affected by age. Data on the ontogeny of these transporters and their clinical relevance are limited. The two major transporters are adenosine triphosphate (ATP)-binding cassette (ABC) and the solute carrier (SLC) transporters. In general, the expression of drug transporters appears low during the fetal and neonatal periods, but augments from 7 years of age onward. 16 Data on age-related maturation from infancy to early childhood are currently limited.
One of the most studied transporters is ABCB1, which supports renal CL of daptomycin. Interestingly, the development of ABCB1 is also dependent on the organ type, with stable expression in the intestines of adults and pediatric patients, low hepatic expression in neonates and infants until 12 months of age, and low renal expression until 3 to 6 months of age. 16, 17 The renal CL of daptomycin is higher in neonates and infants than in adults due to the enhancement of ABCB1 expression that mediates renal tubular secretion despite their immature GFR. 16 
Population-Based Pharmacokinetic Modeling and Bayesian Estimation
While extrapolating pharmacologic data from adults may produce meaningful predictions in older children and adolescents, age-related maturational changes in neonates, infants, young children, and individuals with pediatric-predominant diseases (including CF and Kawasaki disease) require PKPD studies be conducted directly in these pediatric groups to serve the unmet needs. 18 In the effort to optimize and individualize drug dosing regimens, pharmacometrics is utilized as a quantitative approach to understand and predict the PK and PD of a drug. Pharmacometric modeling, specifically population-based PK (PopPK), allows us to integrate different factors (or covariates) to ultimately characterize a population average, with intersubject and intrasubject variabilities of PK parameters, including Vd and CL, that determine drug dosing. 19 The incorporation of covariates, particularly weight and age, as explained above, is integral to optimizing the use of drugs in pediatric patients because this approach can address the wide age spectrum across the diverse pediatric age groups. 20 The use and acceptance of PopPK (which integrates nonlinear mixed-effects modeling) continues to improve our understanding of PKPD in children. 21 Furthermore, PopPK can be used to individualize drug dosing directly in the patient care setting to improve the precise achievement of a therapeutic goal that minimizes drug toxicity while maximizing clinical benefit. 22 Bayesian estimation can be incorporated into PopPK modeling to enhance prediction of PK parameters and measures of drug exposure, including drug concentrations and area-under-time-concentration curves. 23 The use of the Bayesian approach facilitates derivation of more accurate predictions for PK, as well as the PD of drugs. 24 The Bayesian approach assumes that covariates of interest are random and introduces uncertainty, which can be better understood with prior knowledge of drug behavior in that population. The "Bayesian prior" is the construction of the probable PK parameters for a patient, obtained from prior PK studies in the relevant age-specific population, that can be applied to that patient. Combining this Bayesian prior with the patient's measured drug concentrations, the estimation and prediction of PopPK parameters are greatly enhanced. Population-based PK modeling with Bayesian estimation is accepted by the US Food and Drug Administration as an approach to drug evaluation in pediatric patients. 25 
Pharmacodynamics
Evaluation of the PD allows us to understand the relationship between drug exposure at the site of infection and the onset, intensity, and duration of pharmacologic effect on the pathogen. 26 Along with the PK, the PD property of an antimicrobial agent can be used to maximize clinical response and prevent toxicities related to therapy. To treat or cure an infection, the antibiotic exposure should be maximized to inhibit (or eradicate) the pathogen and suppress the development of resistance. 27 The PD exposure target must integrate a feature for pathogen susceptibility known as the minimum inhibitory concentration, or MIC. 28 In addition to the MIC, the drug concentration of interest, which should reflect the active unbound moiety, can be the peak, trough, or average concentrations or exposure over a period of time (AUC over 24 hours).
The exposure-response relationship for an antimicrobial agent is more predictable in adults than in pediatric patients. A standard antibiotic dose will generally provide a baseline exposure to elicit a predictable clinical response in adults. However, one standard dose cannot be applied in pediatric patients because substantial variability exists in exposure to an antibiotic across the pediatric age spectrum. Once the age-specific exposure is known in pediatric patients to achieve an equivalent exposure to that demonstrated in adults, the exposure that yields the desired microbiologic and clinical cure in adults is then assumed to be similar in that age group. Notably, the age-specific exposure in pediatric patients, particularly in neonates due to their immature immune function, may differ from the exposure needed to achieve microbiologic and clinical cure in adults; in other words, the drug exposure required in the immune-compromised neonate for cure may be greater than that associated with cure in adults. Currently, no prospective data exist in neonates to validate the exposures required for microbiologic and clinical cure. In addition, underlying genetic and clinical factors that may affect response may also be explored to optimize therapy in both pediatric patients and adults.
An important component of PD for successful treatment of an infection is antibiotic penetration. The degree of antibiotic penetration must be accounted for to ensure adequate drug exposure at the site of infection to maximize therapeutic response. The MIC provided by clinical microbiology depicts susceptibility of a pathogen based on achievable serum concentration. In the scenario where a pathogen is reported resistant to a certain antibiotic, that same antibiotic may still successfully treat the infection if the resistance (assessed by the actual MIC) is not profound and complete and adequate drug exposure can be achieved (eg, treating a urinary tract infection using a drug that highly concentrates in the kidneys). In contrast, even if an antibiotic is reported as susceptible, therapeutic response may not be achieved if drug exposure is inadequate in specific tissue sites, particularly for serious infections, including meningitis and pneumonia, or undrained abscesses.
Appropriate management of central nervous system (CNS) infections requires that antibiotics penetrate the blood-brain barrier to attain concentrations at the site of infection for eradication of the infecting pathogen. Independent of age, the physicochemical property of a drug is the main factor that determines drug distribution into the CNS. In fact, small-sized and highly lipophilic drugs with low protein binding penetrate the blood-brain barrier well. The distribution pathways that are affected by growth and development, and the presence of meningeal inflammation, are also factors that affect overall CNS drug penetration. Antibiotics with good CNS penetration are provided in Table 2 . 29 Penetration of these antibiotics is enhanced when the meninges are inflamed. For pneumonia caused by extracellular pathogens, epithelial lining fluid (ELF) has been used as the target site to determine adequacy of drug exposure. Currently, the literature on ELF-to-plasma ratios is limited to a small number of antibiotics, all of which were evaluated in adults, and comprises beta-lactams (ranging from 0.21 to 1.04, depending on the specific beta-lactam), vancomycin (0.18 to 0.50), aminoglycosides (highly variable hysteresis depending on sampling time and arising from the hydrophilic property of these antibiotics), and fluoroquinolones (>1.0, which represents extensive lung penetration). 30 The presence of hysteresis on a concentration-effect plot implies a delay in time between measured concentration and response, as well as an associated lower peak concentration. Notably, these studies of ELF do not account for redistribution of drugs from the ELF back to plasma because only specific time points after dose administration (rather than over the entire dosing interval) were evaluated. Nonetheless, for all of these distinct infection types, adequate antibiotic exposure implies the need to use free drug concentrations in PKPD studies to account for antibiotic penetration at the site of infection.
Monte Carlo Simulation
To identify the best dosing regimen that achieves microbiologic and clinical cure (and even resistance suppression), a PD exposure target or index should be explicitly defined and incorporated (along with agespecific PK data) to conduct Monte Carlo simulations. The PD indices that vary with antibiotic class must integrate pathogen susceptibility and antibiotic S113 exposure, depicted by free drug peak concentration over MIC (C max /MIC, associated with aminoglycosides), AUC 24 /MIC associated with fluoroquinolones, or the time that free drug concentrations remain above the MIC (fT>MIC), associated with beta-lactams. Currently, the PD exposure targets for antibiotics have originated primarily from preclinical in vitro models, with very limited validation in clinical studies. 27 Furthermore, these limited human clinical investigations were conducted retrospectively in adult patients. As such, there is an evident demand for well-designed studies in pediatric participants, preferably conducted prospectively, to validate PD targets of antimicrobial agents that were derived from preclinical and adult data. Despite improvement in the number of pediatric PK studies in recent decades, the need for PD studies in pediatric participants should be underscored to ensure the optimization of antibiotic dosing required for the cure of different infections over the entire pediatric age spectrum. In addition, protein binding, drug penetration to the site of infection, and immunologic competence that changes with age are important factors that should be evaluated in PD studies.
Clinical Pharmacology Optimizing Bedside Care of Pediatric Infections
Safe and effective antibiotic use in all pediatric age groups, including neonates, requires thorough understanding and application of the quantitative clinical pharmacology that encompasses PKPD. 20 Pharmacologists, pharmacists, and physicians must collectively be equipped to support and integrate PopPK modeling, Bayesian estimation, and simulation methods in the clinical decision-making process that is integral to therapeutic drug monitoring and management to optimize exposure-response and clinical outcome relationships across the pediatric age spectrum. 18 To demonstrate the application of clinical pharmacology to the optimization of pharmacotherapy and its positive impact on the care of pediatric patients with infections, specific antibacterial agents (including beta-lactams, aminoglycosides, and vancomycin) are presented in the subsequent sections. The selection of these antibiotics was based on the availability of studies in pediatric patients and on their PD properties. Antibiotics with unique PD features (including concentration-dependent, time-dependent, and postantibiotic effects) and, more importantly, antibiotics with a sufficient number of PKPD evaluations in pediatric patients are presented. Table 3 describes the PD properties of antibiotics, including those with limited PKPD studies in pediatric patients. Antifungal agents were excluded from this article, but two reviews have been published. 31, 32 Beta-lactams Because of their long-standing safety profile and their broad spectrum of antibacterial activity, beta-lactam antibiotics present the most extensively studied class evaluated for their PKPD properties in pediatric patients. Because this class of antibiotics exhibits timedependent bactericidal but no post-antibiotic effects, the use of beta-lactams can be optimized by increasing the infusion time or the dosing frequency, particularly to treat pathogens with higher MICs (Table 3) . These two approaches align with maximal use of the timedependent PD killing of beta-lactams. Nonetheless, extending the infusion time (which includes prolonged and continuous infusions) has been evaluated more frequently than has increasing dosing frequency (ie, from every 6 to every 4 hours) for its feasible application in the patient care setting. This is particularly valuable in the care of pediatric patients with certain medical conditions (eg, prematurity, CF, or hematologic/ oncologic disorders) that necessitate the use of multiple concurrent medications.
To determine the probability of target attainment (PTA) against Pseudomonas aeruginosa with varying susceptibilities, Monte Carlo analyses in children between 1 and 12 years of age were conducted using different regimens of cefepime, ceftazidime, imipenem/cilastatin, meropenem, and piperacillin/ tazobactam. [33] [34] [35] The PD target to achieve bactericidal activity used in these studies was fT>MIC ࣙ40% for carbapenems and ࣙ50% for penicillins and cephalosporins. For bacteriostatic effect, PD targets ࣙ20% fT>MIC for carbapenems and ࣙ30% fT>MIC for penicillins and cephalosporins were used. Collectively from these studies, prolongation of infusion from 30 minutes to 3 hours and continuous infusion significantly improved the PTA to >90% to achieve bactericidal activity for all antibiotics that were evaluated. [33] [34] [35] This is a clinically relevant finding that can be applied to critically ill children to achieve optimal PTA against moderately susceptible strains of P aeruginosa.
For less susceptible pathogens, increasing the dose alone, without optimizing the PD property of fT>MIC by increasing infusion time, may not always achieve adequate drug exposure. For example, at one institution with elevated MICs among the P aeruginosa isolates, increasing the meropenem dose from 20 mg/kg to 40 mg/kg, administered every 8 hours using 30-minute infusions, resulted in a low, inadequate PTA of 58%. 35 This illustrates that increasing the dose alone without extending the infusion time of beta-lactams may not be sufficient to adequately treat serious antibiotic-resistant infections.
Emerging interest in defining age-related developmental exposures has prompted population-based PKPD evaluations in preterm neonates. [36] [37] [38] [39] [40] [41] To adequately design dosing strategies that reflect maturational development, including nephrogenesis, both gestational and postnatal ages (resulting in postmenstrual age) were used in these studies. To achieve antibiotic microbiologic and clinical efficacy and account for deficiencies in the immune response system expected in neonates, higher PD targets of >60% fT>MIC for meropenem and >75% fT>MIC for ampicillin and piperacillin were employed in these studies. Meropenem was evaluated in preterm and fullterm neonates <2 months old with gestational ages of 23 to 42 weeks. 36, 41 Important covariates for CL were postmenstrual age, weight, and serum creatinine. Meropenem CL increased in older neonates, defined by gestational age and chronologic age. Meropenem 20 mg/kg every 8 hours, infused over 30 minutes, achieved >90% PTA for its bactericidal effect against nosocomial Gram-negative pathogens. 36 However, meropenem 40 mg/kg every 8 hours infused over 4 hours was recommended for less susceptible bacteria, including P aeruginosa, with MIC of 4 to 8 mcg/mL. 36, 41 The PKPD of meropenem was evaluated for the treatment of meningitis and intra-abdominal infections in neonates. 39 For meningitis, meropenem concentrations in the cerebrospinal fluid (CSF) that were measured at various time periods varied from 4.1 to 34.6 µg/mL, which represent an average of 70% (range of 5% to 148%) penetration. For suspected or complicated intra-abdominal infections, meropenem 20 to 30 mg/kg, depending on gestational age and postnatal age, was administered every 8 or 12 hours. Most (ß85% of 200) of these infants experienced clinical therapeutic success and tolerated meropenem well. 38, 39 Similar to meropenem, piperacillin/tazobactam was also studied in premature and term infants ࣘ90 days with suspected or complicated intra-abdominal infections. The CL of piperacillin improved with increasing gestational age at birth, but decreased by 60% when serum creatinine was ࣙ1.2 mg/dL. 42 Piperacillin 80 to 100 mg/kg infused every 8 hours did not meet PD efficacy target for P aeruginosa in ß70% of infants, implying that further studies of higher doses or more frequent or more prolonged infusions are warranted.
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A phase 1, single-dose study of doripenem was conducted in 52 infants up to 12 weeks of postnatal age. 43 Displaying linear PK, neonates <4 weeks had decreased CL and increased mean AUC exposure. The PK of doripenem infused at 5 to 8 mg/kg over 1 hour in these term and preterm infants was similar to those previously reported for other carbapenems in neonates and young infants.
Similar to premature infants, children with CF have altered PK that may necessitate different dosing strategies. Increased CL (eg, aztreonam 100 mL/min in children with CF versus 76 mL/min in healthy participants, P < .01), without a significant change in Vd, has been reported. 4, 44 To prevent subtherapeutic dosing that may result from the increased CL, the PD property of antibiotics should be maximized to optimize dosing in this population. One study showed significant improvement in achieving the PTA of ࣙ65% fT>MIC with the use of 4-to 5-hour prolonged or continuous infusions of ceftazidime 6 grams per day (weight-adjusted for 70 kg). Extended or continuous infusions increased the PTA for pathogens with elevated MIC, even as high as 8 to 12 μg/mL. 4 This is invaluable in patients with CF because they usually have a history of previous exposure to antibiotics for both acute and chronic respiratory infections. 45, 46 Likely due to their repeated antibiotic exposures, reported antibiotic resistance rates are higher in children with CF.
Ceftaroline is the first beta-lactam antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) and, as such, may play a significant role in patients with CF. A case report of a ceftaroline-resistant MRSA strain from a girl with CF was reported after 22 ceftaroline treatment courses using standard adult dosing that achieved suboptimal antibiotic exposure, possibly arising from increased CL and Vd in this patient. This case report prompted a study evaluating the single-dose PK and safety of ceftaroline in children with CF for staphylococcal pneumonia. In this phase 1, open-label, single-dose, prospective study using 10 mg/kg (up to 600 mg) in 20 participants between 6 and 18 years of age, PopPK modeling showed that children with CF have increased ceftaroline CL compared with published data from children without CF. As such, higher dosages are likely to be required in children with CF to achieve adequate exposure for cure and possibly delay the emergence of resistance. 47 In addition to neonates and children with CF, critically ill children may have experienced alteration in PK parameters necessitating changes in dosing strategies. Increased Vd of certain antibiotics, particularly those with high water-solubility, has been reported in critically ill children. For example, the Vd of piperacillin is 0.51 L/kg in critically ill young children versus ß0.28 L/kg in young children who are not critically ill. 33, 48 This increased Vd may potentially result from underlying disease states affecting the interstitial fluid, where increased extracellular fluids observed in thirdfluid spacing increases the Vd.
The optimal PD target for immune-compromised neonates and children is not well-defined. However, one investigator has proposed an aggressive and unvalidated PD target to combat serious P aeruginosa infections in patients with immune-compromised status and maintain free drug concentrations at 100% fT >6 times the MIC. 49, 50 Studies in adults have evaluated a PD target of 100% fT>MIC to improve clinical cure and microbiologic eradication using cefepime, piperacillin/tazobactam, meropenem, and ceftobiprole. 51, 52 Using this PD target in adolescents with febrile neutropenia, a loading dose of 100 mg/kg followed by continuous infusion of piperacillin/tazobactam at 350 to 400 mg/kg/day achieved >99% PTA at an MIC of 4 mg/L. 49 The standard dose of 300 mg/kg/day achieved ß85% PTA, which the authors considered inappropriate for patients with recent intensive chemotherapy, predicted prolonged and profound neutropenia, or fever >39°C because such patients are at increased risk for serious infections.
In conclusion, studies in the different pediatric age groups serve as evidence for the use of various dosing strategies for beta-lactams to enhance their PD target attainment. Strategies for the optimization of betalactam use consist of frequent dosing and extended or continuous infusions that may improve PTA in certain pediatric populations, including individuals who are critically ill, immunocompromised (including premature neonates), have CF, or are infected with pathogens exhibiting high MICs. Outside these specific medical conditions, the PD-guided dosing strategies, as compared to traditional dosing, may not provide additional clinical benefit to patients. Based on a systematic review of limited studies conducted in pediatric patients, the routine use of extended or continuous infusion of beta-lactam antibiotics was not supported by current evidence, as excessive treatment failures have not been reported. 53 Nonetheless, more well-designed prospective trials in pediatric patients, particularly those with underlying diseases that may benefit from PD-guided dosing strategies, are necessary to confirm the clinical value of these dosing strategies to directly affect patient care.
Aminoglycosides
Based on studies in adults using traditional multipledaily dosing of tobramycin and gentamicin, clinical response to these antibiotics is maximized when the C max /MIC ratio is 8 to 10 (Table 3) . 54, 55 This traditional dosing has been associated with decreased resistance patterns, but suppression of P aeruginosa requires a much higher C max /MIC target of 30. 56, 57 To optimize the aminoglycosides' PD features and potentially minimize adaptive resistance, the once-daily (or extended-interval) dosing strategy consolidates multiple doses into one large daily dose to achieve high peak concentrations to effectively eradicate certain bacteria, including those with reduced susceptibility and an MIC >1 μg/mL. 58, 59 With their post-antibiotic effect, once-daily aminoglycoside dosing provides a drug-free interval where serum concentrations can fall below the MIC of susceptible organisms, yet retain inhibition of bacterial growth. As an additional clinical benefit, the extended-interval strategy may reduce nephrotoxicity because it allots sufficient time for complete elimination of the drug prior to re-administration. 59 ,60 While C max /MIC is the PD index used for aminoglycoside efficacy, the clinical significance of AUC monitoring requires further exploration. Current dose-fractionation studies reveal that AUC/MIC may be correlated to the development of P aeruginosa resistance. 55, 56 The efficacy and safety of extended-interval dosing was compared to traditional thrice-daily dosing of tobramycin at 10 or 15 mg/kg/day in a meta-analysis of four randomized, controlled studies that evaluated both pediatric and adult participants with CF. 61 No significant differences in clinical outcomes (including pulmonary function, nutritional status, time to first pulmonary exacerbation after treatment course, and ototoxicity) were reported between these dosing strategies. However, the advantage of the extended-interval dosing strategy was decreased nephrotoxicity, defined by serum creatinine and urinary renal biomarkers.
Gentamicin, tobramycin and, to some extent, amikacin have been thoroughly examined in pediatric patients. While tobramycin and amikacin are the primary aminoglycosides used to treat pulmonary infections caused by P aeruginosa in CF, gentamicin has been more widely used for decades for the treatment of suspected or proven bacterial sepsis caused by enteric bacilli in neonates. Currently, this PD-guided, oncedaily strategy is standard of care for adults and has been evaluated in children with CF, children with febrile neutropenia, and neonates. 55, 57, [60] [61] [62] Children with CF commonly receive multiple courses of aminoglycoside therapy because they have pulmonary infections caused by P aeruginosa throughout their lifetime. As a result, the infecting bacteria often have decreased antibiotic susceptibility owing to frequent previous antibiotic exposure. 57 Furthermore, adequate antibiotic concentrations are difficult to achieve in the ELF and mucosal surfaces in these infected children. In addition, patients with CF tend to have increased drug Vd and CL, which necessitates higher antibiotic doses. Collectively, for these reasons, extended-interval dosing provides a rational strategy to employ in these patients to maximize clinical benefit.
Pharmacodynamically, once-daily dosing can achieve antibiotic exposures that are effective against less susceptible bacteria. In fact, tobramycin 10 mg/kg/day (which achieves C max of 20 to 40 μg/mL, trough concentrations <1 μg/mL, and AUC 24 of 60 to 120 mg-h/L) and once-daily amikacin 30 to 35 mg/kg/day (which achieves C max of 80 to 120 μg/mL, trough concentrations <1 μg/mL, and AUC 24 of 235 ± 110 mg-h/L) can reach the PD index of C max /MIC ࣙ10 for less susceptible pathogens, specifically those with MICs up to 2 μg/mL for tobramycin and 4 μg/mL for amikacin. 57 Because of the PD property of aminoglycosides, the routine use of extended-interval dosing is supported by the Cystic Fibrosis Foundation. 63 Gentamicin is bactericidal against Gram-negative pathogens and has been used widely in neonates for decades. Multiple elements affect the PK of gentamicin in neonates, including postconceptional age, weight, and renal function. The PD index usually targeted in this population is C max of 5 to 10 μg/mL for efficacy (assuming MIC ࣘ1 μg/mL) and trough concentrations <1 to 2 μg/mL to minimize toxicity. 60 The high variability and unpredictability of gentamicin's PK reinforces the value of individualized dosing and therapeutic drug monitoring, particularly in premature neonates. 64 In fact, a multicenter study demonstrated the rapid achievement of therapeutic concentrations using an individualized nomogram-based dosing strategy, with less need for measuring drug concentrations and dosing adjustments. 65 With an evidently prolonged half-life due largely to the neonate's immature renal function and, to a lesser extent, increased Vd, once-daily dosing is reasonable and, especially in extreme preemies, dosing every 36 to 48 hours may be necessary. 62 Based on a comparative meta-analysis of 574 neonates who were <28 days of life, once-daily dosing, as compared with multiple-daily dosing, improved attainment of peak concentrations ࣙ5 μg/mL and trough concentrations <2 μg/mL. 60 Efficacy and toxicity, including ototoxicity and nephrotoxicity (assessed by changes in serum creatinine and renal biomarkers) were comparable between these dosing strategies. Accordingly, neonates who receive oncedaily gentamicin dosing and for a duration that is less than 48 to 72 hours may not routinely require the therapeutic monitoring of drug concentrations or assessments of renal function for toxicity.
Children may experience febrile neutropenia as a result of cancer chemotherapy or transplantation immunosuppressive therapy. Depending on patient age, gentamicin or tobramycin administered at 6 to 10.5 mg/kg/day achieves C max /MIC ß10, which is S117 necessary to treat infections caused by P aeruginosa in these children. [66] [67] [68] Age-related differences in renal CL necessitate a higher milligram per kilogram dose of gentamicin for younger children with febrile neutropenia. In addition, once-daily administration is preferred to thrice-daily administration to maximize efficacy and minimize nephrotoxicity and has the concomitant benefit of less nursing time for drug administration. With minimal post-antibiotic leukocyte enhancement because of their neutropenia, loading doses to achieve therapeutic peak concentrations early in the course of therapy may be advantageous in these patients.
Aminoglycosides may cause a concerning adverse effect that limits their use, nephrotoxicity. Prospective randomized trials have documented the advantage of once-daily over multiple-daily dosing in reducing the occurrence of nephrotoxicity. 55, 69, 70 In proximal renal tubular epithelial cells, aminoglycosides can accumulate and thereby result in nephrotoxicity. Once-daily dosing exposes the renal cells to high, intermittent concentrations that saturate drug uptake and consequently lead to an increase in drug excretion. 55, 60 Furthermore, once-daily dosing facilitates sufficient time for elimination of the drug to negligible concentrations before the subsequent dose is administered, thereby preventing nephrotoxicity. In a study of neonates, oncedaily gentamicin dosing resulted in reduction in the ratio of urinary N-acetyl-βD-glucosaminidase to creatinine, which appears to be a sensitive marker for nephrotoxicity. 69 The other significant adverse effect of amingoglycosides is ototoxicity, in which free radicals irreversibly damage the cochlear and vestibular hair cells. The occurrence of ototoxicity has not been associated with frequency of aminoglycoside administration. 23, 55 Vancomycin Vancomycin exhibits time-dependent bactericidal activity, with some post-antibiotic effect lasting 0.7 to 2.6 hours for Staphylococcus aureus and 4.3 to 6.5 hours for Staphylococcus epidermidis. 71 Based on adult PKPD studies, the efficacy surrogate for vancomycin in treating invasive MRSA infections is achieving AUC/MIC ratio ࣙ400, with the MIC determined by Etest R (Biomérieux; Marcy-l'Étoile, France). An AUC/MIC ratio ࣙ400 corresponds to a minimum concentration of 15 to 20 μg/mL when the MIC is 1 μg/mL in adults. 72, 73 However, in infants and children >3 months of age, this PD index may be achieved with lower trough concentrations of 8 to 10 μg/mL when the MIC is ࣘ1 μg/mL (evaluated using broth microdilution and Etest methods). 74, 75 This crucial observation was based on two independent PK studies that incorporated robust Bayesian estimation and Monte Carlo simulations, emphasizing the fact that pediatric response differs from adult response and adult data may not always be applicable. Furthermore, there are insufficient PD data to demonstrate improved outcomes with attainment of vancomycin AUC/MIC ࣙ400 in pediatric patients and the data come primarily from retrospective analyses. [76] [77] [78] [79] Prospective, comparative PD studies in pediatric patients are necessary to validate the PD target that so far has been evaluated only in adults.
Optimal vancomycin use requires incorporating both age-related PK developmental changes and MIC data. PK studies in pediatric participants suggest lower trough concentrations will achieve AUC/MIC ࣙ400 but PD outcomes data are limited by inconclusive retrospective studies. In the largest PopPK study in pediatric participants >3 months (N = 702), the integration of weight, age, and serum creatinine (which, in aggregate, reflects developmental renal maturation) was necessary to estimate vancomycin CL. 75 Using AUC/MIC ࣙ400 as the PD target index due to lack of current pediatric studies, increased vancomycin doses at 60 to 80 mg/kg/day (depending on age, serum creatinine, and MIC by Etest) was necessary to achieve adequate PTA. Notably, vancomycin AUC/MIC, compared with trough concentrations, was a more achievable and, hence, realistic target in children. Higher doses of 90 to 100 produced excessively high AUCs of 840 to 940 mgh/L, with trough concentrations exceeding 20 μg/mL. 75 This excessive exposure may potentially place patients at unnecessary and increased risk of nephrotoxicity, as concluded by multiple studies in children with trough concentrations ࣙ15 μg/mL, AUC >800 mg-h/L, and doses ࣙ10 mg/kg. [80] [81] [82] Because vancomycin is eliminated primarily via GFR with some active tubular secretion, dosing at 15 mg/kg every 8 hours (ie, 45 mg/kg/day) may be most appropriate empirically for older children with acute renal insufficiency. 83, 84 Furthermore, children with acute renal insufficiency generally do not have chronic disease and, hence, may require close monitoring because recovery of renal function may occur during vancomycin therapy, with markedly improved CL.
Population-based PK studies with Bayesian estimation in preterm and full-term neonates have evaluated vancomycin doses ranging from 15 to 60 mg/kg/day administered intermittently every 8 to 24 hours or as continuous infusions. [85] [86] [87] [88] Notably, these studies did not evaluate PTA by AUC/MIC ࣙ400, which is the PD target best linked to successful treatment outcomes in adults. However, one study evaluated the association between AUC and trough concentrations in 240 neonates, with 1702 vancomycin concentrations. 89 This PopPK study derived a model for vancomycin CL that was based on weight, postmenstrual age, and serum creatinine; using Monte Carlo simulations with Bayesian estimation, trough concentrations ranging from 7 to 11 μg/mL were highly predictive of an AUC 24 of >400 μg-h/mL in at least 90% of neonates. Doses to achieve this PKPD target ranged from 15 to 20 mg/kg every 8 to 12 hours, depending on postmenstrual age and serum creatinine. The incidence of vancomycin-associated nephrotoxicity reported in neonates has been low, ranging from 1% to 9%. 90 The high variability of vancomycin's PK in preterm and full-term neonates necessitates therapeutic drug monitoring, preferably with AUC estimation, to ensure adequate therapeutic exposure. 29 Recent PK data highlighting differences in trough concentrations required to achieve the PD vancomycin exposure target of AUC/MIC ࣙ400 in children and adults prompts the need to investigate the optimal monitoring strategy that can be integrated into clinical practice. 74, 75 The minimal PD evidence in children, coupled with the differences in trough concentrations, supports the monitoring of vancomycin exposure by AUC because it is a more relevant and achievable PD target. Furthermore, AUC targeting and monitoring may prevent excessive dosing, frequent dosing adjustments, and potentially adverse effects. A PopPK study with Bayesian estimation in 138 pediatric participants demonstrated improved the accuracy and precision of estimating AUC using peak and trough concentrations compared with trough concentrations alone. 91 However, one study in adults suggests that a single sample may be adequate to predict appropriate dosing.
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Current Challenges With Potential Solutions
Antimicrobial agents are widely used in pediatric patients, especially neonates and young infants. Despite extensive use of antibiotics, the PKPD in this population are limited, arising from its historical exclusion from clinical trials. Legislation via the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) support and mandate pediatric research to improve drug product labeling. 93 The PREA legislation authorizes the National Institutes of Health to implement research programs through funding clinical trials to study off-patent drugs in all children, including neonates and young infants. BPCA provides economic incentives to companies in exchange for important clinical data that address an important medical need in pediatric patients. Continued efforts are necessary to promote the need for PKPD evaluations of drugs (both generic and new) across the broad pediatric age spectrum.
While quantitative pharmacology is increasingly employed to evaluate the PKPD of drugs in pediatric patients, the off-label use of drugs without PKPD data in the pediatric setting remains unacceptably high. Furthermore, the integration of PKPD into clinical practice still needs improvement. The link between in vitro and in vivo PKPD properties and their extrapolation to the clinical use of drugs in pediatric patients needs to be communicated clearly to clinicians in a manner that changes practice. 26 One approach may be to address the quality of PKPD studies by developing an evidencebased grading scheme that enables clinicians, many of whom are not pharmacologists, to appreciate the strength of the evidence. 21 In addition, new evidence in pediatric patients, including those who are obese, often emerges post-marketing and should be integrated into clinical practice by updating drug formularies.
Despite the successful use of allometric weight in pediatric patients to estimate PK parameters, errors may still occur, especially for drugs undergoing hepatic metabolic CL. Physiologically based pharmacokinetic models are emerging to facilitate simulations of PK profiles under varying physiological conditions. 94 These models integrate data that are traditionally not integrated into PK modeling, including drug properties, physiological changes, and biological parameters, which may differ between individuals due to age and disease states. The biological and mechanistic basis of PBPK models closes the gap between tissue concentrations and observed therapeutic or toxic effects. A unique approach that combines the full PBPK and standard PopPK analyses, which has been termed as "semiphysiological-based PK," has been used to characterize and predict the developmental changes of important elimination pathways, like GFR, across the human life span, from neonates to adults. This system-based pharmacometric methodology permits the development of one model that simultaneously describes multiple drugs (eg, aminoglycosides and vancomycin) because they undergo similar elimination. 95 The ethics and logistics of blood sampling (both by number and volume) in pediatric patients present a challenge to conducting PKPD studies with enough samples to accurately estimate PK parameters. Traditionally, a whole blood volume up to 5 mL and sampling 5 to 8 times within a dosing interval were necessary to accurately describe PK parameters in pediatric patients. Innovative strategies to overcome this challenge have been attempted and include sparse sampling, microsampling, dried blood spot technique, and opportunistic study design.
Sparse sampling is more practical than the traditional intensive approach and has been increasingly appearing in published PK studies evaluating pediatric populations. 40, 42, 75, 91, 96 Sparse sampling provides one major advantage: it reduces the number of blood draws and, when applied in population-based modeling, provides estimation for both individual and population PK parameters with inter-subject, intra-subject, and "unexplained" residual variabilities. 21 To accommodate the reduced number of blood samples, a larger participant sample size (often >100) must be used to produce meaningful results in PopPK modeling. Similar to sparse sampling, microsampling reduces the overall blood volume needed: whereas sparse sampling reduces the frequency, microsampling reduces the actual volume drawn during sampling. In fact, microsampling requires a volume <50 μL, which can be collected by skin prick. 97 Dried blood spot is a sampling technique that utilizes an ultra-low volume (ie, 30 μL of whole blood, which is 20 times lower than traditional venous or arterial samples) to evaluate the PK of drugs. It is stable and reproducible on paper filters. In addition, dried blood spot sampling eliminates the need for centrifugation or freezing of samples and measurement of drug concentration in whole blood. As such, the advantages of dried blood spot sampling are low sample volume, minimal personnel training, no sample processing, room temperature storage, and simple bioanalytical analysis. 98 Using this technique, the estimates and precision of metronidazole PK parameters for premature infants in one small study were similar between plasma and dried blood spot samples. 99 Of concern though, metronidazole concentration in the dried blood spot samples was 15% lower than in the plasma samples. Limited pediatric PK studies currently utilize this technique. 99, 100 Future studies should explore this sampling strategy and identify class-and drug-specific concentration differences between dried blood spot and plasma samples.
The opportunistic study design capitalizes on standard clinical care to perform clinical research. This design is perceived as minimal risk, diminishes researchrelated costs, and enhances parental consent. While the opportunistic design does not permit administration of study drug to patients because the drug is already prescribed as standard of care, it provides four main advantages and therefore is attractive to use in pediatric research. First, this design evaluates a drug that is already prescribed by clinical indication. Second, it optimizes the collection for PK samples by coinciding timing with routine labs to minimize pricking. Third, for drugs with active therapeutic drug monitoring, data on drug concentrations are already measured by the clinical laboratory and available for use in PK modeling. Finally, the opportunistic study design utilizes scavenged samples to maximize testing on drawn blood that would otherwise be left unused.
Scavenged PK sampling is a minimal-risk approach that can provide meaningful information related to the development of PK models but cannot inform dosing recommendations. The utility of scavenged sampling in providing definitive dosing recommendations may be drug dependent and needs to be further explored. 42 Opportunistic studies have been used to extract important findings for the preliminary construct of phase 1 through 3 trials and enhance the dosing of currently marketed antimicrobial agents in pediatric populations. 75, 101, 102 
Conclusions
Children of all ages may experience variability in response to antimicrobial agents, thereby potentially leading to undesired subtherapeutic or unanticipated toxic effects when PKPD data are unavailable. This underscores the importance of thoroughly understanding the age-related physiologic changes that occur with normal human growth and development. Regulatory agencies through PREA are requiring PK and efficacy data to optimize pharmacotherapy in pediatric populations, including neonates. While the availability of PK data in these populations has improved over the past decades, PKPD outcome assessments remain infinitesimal. Rational antibiotic dosing can only improve with more well-designed PKPD pediatric studies in the future.
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